A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With
Chemoimmunotherapy
EGFR mutation
Immune checkpoint inhibitor
Non–small cell lung cancer
Osimertinib
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
19
05
2022
revised:
04
07
2022
accepted:
23
07
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
The use of immune checkpoint inhibitors (ICIs) with chemotherapy has increased the survival of patients with advanced NSCLC. Nevertheless, the efficacy of ICI treatment for NSCLC with This study performed a retrospective analysis of the association between clinical characteristics and ICI efficacy in patients with Among 80 patients with The PFS of osimertinib might be a predictor of PFS of chemoimmunotherapy in patients with
Identifiants
pubmed: 36082280
doi: 10.1016/j.jtocrr.2022.100388
pii: S2666-3643(22)00112-6
pmc: PMC9445370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100388Informations de copyright
© 2022 The Authors.
Références
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Cancer Immunol Immunother. 2021 Jan;70(1):101-106
pubmed: 32648165
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Sci Immunol. 2020 Jan 31;5(43):
pubmed: 32005679
Lancet Oncol. 2016 Dec;17(12):1643-1652
pubmed: 27751847
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Front Immunol. 2022 Feb 28;13:832419
pubmed: 35296087
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Thorac Oncol. 2021 Oct;16(10):1622-1626
pubmed: 34561035
NPJ Precis Oncol. 2021 May 17;5(1):41
pubmed: 34001994
Ann Oncol. 2022 May;33(5):466-487
pubmed: 35176458
Ann Oncol. 2019 Aug 1;30(8):1311-1320
pubmed: 31086949
Mol Cancer. 2021 Feb 4;20(1):27
pubmed: 33541368
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Front Oncol. 2021 Mar 11;11:639947
pubmed: 33777802
Cancer Med. 2019 Apr;8(4):1521-1529
pubmed: 30790471